Medical Devices & Technology

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) today unveiled new eight-year clinical data, confirming the exceptional long-term performance of its RESILIA tissue technology in aortic surgical valves. The data demonstrate significant improvements in patient outcomes, reinforcing the company's leadership in structural heart solutions.

The new findings, presented at the Heart Valve Society Annual Meeting, provide compelling evidence that patients receiving aortic surgical valves with RESILIA tissue experienced significantly better long-term outcomes compared to those with non-RESILIA tissue valves. These results highlight the value of Edwards’ innovation in delivering superior durability and performance, crucial for improving patient care and reducing the need for reoperations.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, has announced its financial results for the first quarter ended March 31, 2025. The company delivered impressive growth across key product categories, including Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), positioning itself for continued success in the structural heart market.

Strong Sales Growth Drives First Quarter Results

In Q1 2025, Edwards Lifesciences reported total sales of $1.41 billion, reflecting a robust 6.2% increase year-over-year, or 7.9% on an adjusted basis. The company also posted a solid earnings per share (EPS) of $0.622, with adjusted EPS of $0.64, reinforcing its strong financial position.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) has announced the U.S. Food and Drug Administration (FDA) approval of its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for use in patients with asymptomatic severe aortic stenosis (AS). This groundbreaking approval marks the first-ever FDA authorization for TAVR in asymptomatic patients, potentially transforming the treatment landscape for those with this critical condition.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) has announced its participation in the highly anticipated BofA Securities 2025 Health Care Conference, scheduled for Tuesday, May 13, 2025. The company's leadership, including CEO Bernard Zovighian and CFO Scott Ullem, will take part in a fireside chat at 10:40 a.m. Pacific Time. The discussion will be accessible to investors and healthcare professionals through a live webcast available on the Edwards Lifesciences investor relations website at http://ir.edwards.com. An archived version of the session will be accessible later in the day for those unable to attend the live event.

SHERIDAN, WYOMING – May 7, 2025 – A new randomized controlled trial (RCT) has revealed significant advancements in rotator cuff repair, showing that augmentation with the REGENETEN Bioinductive Implant can substantially reduce the risk of re-tears, offering hope for better outcomes in patients undergoing full-thickness rotator cuff repairs. The study's findings have the potential to set a new standard of care in orthopedic surgery.

Understanding the Challenge of Rotator Cuff Repairs

Rotator cuff repairs are among the most commonly performed orthopedic procedures, with an estimated 750,000 surgeries taking place annually in the United States alone. However, the procedure is not without its challenges, as up to 25% of patients experience re-tears, often leading to additional treatments and prolonged recovery times.

SHERIDAN, WYOMING – May 7, 2025 – The growing prevalence of rotator cuff tears, coupled with increasing patient expectations, has sparked a reevaluation of traditional surgical approaches. With more than 750,000 rotator cuff repairs performed annually in the U.S. and the number rising steadily, it’s clear that surgical interventions must evolve to meet the challenges of faster recovery times, improved functional outcomes, and better patient satisfaction. The latest advancements, particularly bioinductive repair using the REGENETEN Bioinductive Implant, present promising alternatives to the established methods of rotator cuff surgery.

SHERIDAN, WYOMING – May 6, 2025 – Zimmer Biomet Holdings, Inc., a global leader in medical technology, has officially launched the "You’ll Be Back" campaign, led by their Chief Movement Officer, Arnold Schwarzenegger. The campaign aims to support millions of individuals suffering from joint pain by offering a unique online community. This initiative seeks to empower people with the knowledge and resources they need to make informed decisions about their mobility and overall health.

The "You’ll Be Back" campaign invites those experiencing limited mobility due to joint pain in areas such as the hip, knee, and shoulder to share their personal stories, join a supportive community, and connect with qualified physicians. Schwarzenegger, an advocate for fitness and mobility, has committed to driving this movement by personally reading submitted stories and selecting participants for a motivational docuseries.

SHERIDAN, WYOMING – May 6, 2025 – The healthcare industry has long relied on traditional training methods for healthcare professionals (HCPs), but recent challenges highlighted by the COVID-19 pandemic have underscored the urgent need for innovation in medical education. Enter Virtual Reality (VR), a transformative tool that is revolutionizing the way healthcare workers are trained and empowering them to deliver better care while improving patient outcomes.

As hospitals and medical institutions continue to face staffing shortages, burnout, and the need for enhanced medical education, VR is emerging as a solution that can help fill critical gaps. By offering immersive, repeatable training experiences, VR technology provides healthcare workers with the opportunity to develop and refine their skills, all while alleviating some of the pressure on experienced professionals and offering tangible benefits to patients.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, has announced its fiscal 2025 second-quarter financial results, highlighting strategic investments and operational resilience despite a challenging macroeconomic environment. The company reported a revenue increase of 4.5% year-over-year, driven by organic growth, currency-neutral revenues, and a focus on operational efficiency.

BD's continued commitment to innovation and market leadership is evident as it invests in manufacturing capacity and product advancements across its key segments. This article delves into the company’s financial performance, strategic initiatives, and future growth outlook, underlining its position as a driving force in the global healthcare market.

SHERIDAN, WYOMING – May 6, 2025 – Stryker Corporation (NYSE: SYK) has announced its operating results for the first quarter of 2025, showing significant growth in both reported and organic sales, underscoring the company’s strong market performance. The global leader in medical technology posted a notable 11.9% increase in net sales, achieving $5.9 billion, with organic sales growth reaching 10.1%.